Sean: Through using Google, I was able to find a CytoDyn labeled summary analysis of the CD02 phase 3 trial that was the predicate for the BLA. The summary indicated that there were 52 patients enrolled who had failed on the SOC drugs and that 40 of them requested placement in an extension trial that the FDA had authorized. I obviously have no access to their medical histories and have no idea how these patients fared after the FDA ordered the hold and required CYDY to halt supplying them with LL. But, as I indicated in my post, I find it plausible that all or many of them may have regressed without LL and that some of their doctors may have contacted CYDY and/or the FDA to seek restoration of LL for their patients. So I am speculating based on the assumption that LL is effective and safe for HIV patients, even Multi Drug Resistant patients, and that LL's absence would have negative consequences for those patients; and that, in the face of such circumstances, some of their doctors might reach reach out for help for them.